VERV - Verve Therapeutics Inc
IEX Last Trade
6.71
0.580 8.644%
Share volume: 2,854,469
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.13
0.58
9.46%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-07 | 2023-03-02 | 2023-05-15 | 2023-08-10 | 2023-11-07 | 2024-02-27 | 2024-05-08 | |
| Total revenue | 0.000 | 929.000 K | 1.012 M | 1.404 M | 2.093 M | 3.117 M | 5.144 M | 5.695 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 929.000 K | 1.012 M | 1.404 M | 2.093 M | 3.117 M | 5.144 M | 5.695 M | |
| inf% | 8.93% | 38.74% | 49.07% | 48.92% | 65.03% | 10.71% | |||
| Operating expenses | 42.192 M | 44.789 M | 48.722 M | 59.663 M | 60.676 M | 55.451 M | 59.092 M | 62.539 M | |
| Selling general and admin | 9.067 M | 9.592 M | 11.439 M | 12.553 M | 13.416 M | 11.686 M | 12.281 M | 14.163 M | |
| Research and development | 33.125 M | 35.197 M | 37.283 M | 47.110 M | 47.260 M | 43.765 M | 46.811 M | 48.376 M | |
| Total expenses | 42.192 M | 44.789 M | 48.722 M | 59.663 M | 60.676 M | 55.451 M | 59.092 M | 62.539 M | |
| 6.16% | 8.78% | 22.46% | 1.70% | -8.61% | 6.57% | 5.83% | |||
| Operating income | -42.192 M | -43.860 M | -47.710 M | -58.259 M | -58.583 M | -52.334 M | -53.948 M | -56.844 M | |
| Ebit | -42.192 M | -43.860 M | -47.710 M | -58.259 M | -58.583 M | -52.334 M | -53.948 M | -56.844 M | |
| Pretax income | -40.946 M | -45.190 M | -41.032 M | -51.975 M | -53.807 M | -45.691 M | -48.320 M | -48.630 M | |
| 10.36% | -9.20% | 26.67% | 3.52% | -15.08% | 5.75% | 0.64% | |||
| Income tax | 0.000 | 0.000 | 53.000 K | 0.000 | 176.000 K | 67.000 K | 32.000 K | 106.000 K | |
| Net income basic | -40.946 M | -45.190 M | -41.085 M | -51.975 M | -53.983 M | -45.758 M | -48.352 M | -48.736 M | |
| -10.36% | 9.08% | -26.51% | -3.86% | 15.24% | -5.67% | -0.79% | |||
| Net income | -40.946 M | -45.190 M | -41.085 M | -51.975 M | -53.983 M | -45.758 M | -48.352 M | -48.736 M | |
| -10.36% | 9.08% | -26.51% | -3.86% | 15.24% | -5.67% | -0.79% |